SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Epigral informs about press release

20 Nov 2023 Evaluate

Epigral has informed that the Company opens its first Research and Development Centre (R&D Centre) at Changodar, Ahmedabad, Gujarat. The detailed Press Release is attached.

The above information is a part of company’s filings submitted to BSE.

Epigral Share Price

1329.30 0.50 (0.04%)
05-May-2026 12:28 View Price Chart
Peers
Company Name CMP
BASF India 3645.70
Tata Chemicals 795.00
SRF 2528.40
Pidilite Inds. 1358.80
Deepak Nitrite 1765.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×